Figure 6.

Syringaresinol-induced vasorelaxation is attenuated by the inhibition of PLC/Ca²⁺/AMPK and PI3/Akt pathways. Endothelium-intact aortic rings pre-contracted with PhE (1 µM) were incubated with U73122 (U, 5 µM), Compound C (CC, 10 µM), Wortmannin (Wt, 100 nM), and BAPTA-AM (BA, 5 µM) for 30 min, followed by treatment with syringaresinol (SY, 30 µM) for 40 min. (A) The vascular relaxation was determined by the same method as described in Figure 1. (B) The level of cGMP was determined in the tissue homogenates using a cGMP assay kit. All data shown are the mean ± SD (n ≥ 5). ^*P < 0.05 and ^**P < 0.01 versus treatment with syringaresinol alone.